These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17627237)

  • 21. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation.
    Ravindran VK; Moore RH; Dunseath G; Luzio SD; Owens DR; Baboolal K
    Transplantation; 2009 Jun; 87(12):1870-6. PubMed ID: 19543067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients.
    Ozbay LA; Møller N; Juhl C; Bjerre M; Carstens J; Rungby J; Jørgensen KA
    Diabet Med; 2012 Dec; 29(12):e440-4. PubMed ID: 23003106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study.
    Duijnhoven EMV; Boots JMM; Christiaans MHL; Wolffenbuttel BHR; Hooff JPV
    J Am Soc Nephrol; 2001 Mar; 12(3):583-588. PubMed ID: 11181807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with glucose metabolism disorders after kidney transplantation.
    Brzezińska B; Junik R; Kamińska A; Włodarczyk Z; Adamowicz A
    Endokrynol Pol; 2013; 64(1):21-5. PubMed ID: 23450443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy.
    Konrad T; Steinmüller T; Vicini P; Toffolo G; Grewerus D; Schüller A; Bechstein WO; Usadel KH; Cobelli C; Neuhaus P
    Transplantation; 2000 May; 69(10):2072-8. PubMed ID: 10852599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
    Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
    Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
    Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction.
    Boots JMM; van Duijnhoven EM; Christiaans MHL; Wolffenbuttel BHR; van Hooff JP
    J Am Soc Nephrol; 2002 Jan; 13(1):221-227. PubMed ID: 11752041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D; Charpentier B; Abramovicz D; Lang P; Rostaing L; Rifle G; Vanrenterghem Y; Berthoux F; Bourbigot B; Delahousse M; Chalopin JM; Cassuto E; Lefrançois N
    Transplantation; 2010 Jun; 89(12):1511-7. PubMed ID: 20386144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.